Adagio Medical has announced the appointment of Todd Usen as the company’s new chief executive officer (CEO) and director, and Orly Mishan as the board of directors’ chairperson.
Both transitions are effective from 13 December this year.
Go deeper with GlobalData
The company’s founder, Olav Bergheim, has stepped down from his roles as CEO and chairperson but will continue to serve as an adviser for a year.
Before his appointment at Adagio, Usen worked as Minerva Surgical’s president and CEO, where he led the company through a successful restructuring and significant growth.
He also held the position of CEO at Activ Surgical, where he oversaw Food and Drug Administration (FDA) / CE clearance of surgical imaging technology and spearheaded fundraising efforts that amassed more than $92m.
Usen’s experience extends to leading more than $2bn business as president of the Medical Systems Group at Olympus Corporation, where he was instrumental in strategic expansion, operational restructuring, and mergers and acquisitions.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataHis career also encompasses executive roles at Boston Scientific Corporation and Smith and Nephew.
At present, Usen serves as Rob Surgical’s executive chairman, NeoPredics’ chairman, and Alesi Surgical’s director.
Usen said: “I’m thrilled to join Adagio at this important junction in the company’s history, supporting initial commercial efforts in Europe, and the FULCRUM-VT trial enrolment in the US.
“With a growing body of evidence demonstrating both the safety and effectiveness of Adagio’s ultra-low temperature cryoablation technology and marked enthusiasm of users in both Europe and North America, I believe that Adagio’s VT Cryoablation System with vCLAS catheter will become the future standard of care for treatment of patients with ventricular tachycardia.”
Based in California, US, Adagio is a medical device company that specialises in developing cryoablation technologies aimed at creating treatments for various cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, ventricular tachycardia, and atrial flutter.
